High throughput DAR determination of brentuximab vedotin
May 27 2020
Drug-to-antibody ratios (DAR) of antibody-drug-conjugates (ADCs) such as brentuximab vedotin is important for their therapeutic efficacy and pharmacokinetics. Therefore, control of DAR is a key factor for ADC quality control. Given that, it is important for QC purposes to obtain a satisfying resolution of all DARs and the resulting average ratio whilst performing the separation in the shortest time.
Brentuximab vedotin (Adcetris®) is a cysteine conjugated ADC targeting different types of lymphoma with an average DAR of 4. Typically, this 2nd generation ADC is analysed by hydrophobic interaction chromatography (HIC).
In this application note YMC’s latest hydrophobic interaction chromatography column, BioPro HIC HT, was used. A mobile phase of sodium phosphate buffer at neutral pH with decreasing gradients of the lyotropic salt ammonium sulphate was used. The rigid 2.3 μm non-porous polymer particles are pressure tolerant up to 400 bar and allow rapid analyses through increased flow rates without loss of resolution. This allows flow rates to be increased by 2.5 times with savings of about 60% in time.
In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Aug 21 2022 Chicago, IL, USA & Online
Aug 22 2022 Frankfurt, Germany
Aug 27 2022 Maastricht, Netherlands
Aug 28 2022 Lisbon, Portugal
Sep 07 2022 Chiba, Japan